article thumbnail

Genomic score predicts patients' progression to multiple myeloma

Broad Institute

To make the MM-like score more clinically accessible, the team is developing a test based on liquid biopsies instead of bone marrow biopsies to collect DNA. The score, called an MM-like score, assesses the severity of disease and risk of progression to active cancer, with higher scores indicating faster progression.

DNA
article thumbnail

Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management

LifeSciVC

The ability of modifying RNA enabled us to sidestep many of the potential risks associated with permanent DNA editing. We aimed to achieve this by modifying and modulating proteins by precisely changing a single alphabet on RNA with the use of an oligonucleotide (think short stretches of chemically modified RNA or DNA).

RNA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche

BioPharma Drive: Drug Pricing

Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. © 2025 TechTarget, Inc. or its subsidiaries. All rights reserved. TechTarget, Inc.s

FDA
article thumbnail

The Magic of Fast Feedback Loops

Codon

DNA sequencing and synthesis costs have dropped precipitously, in part, because maintaining Carlson curves became a rallying point for the field. By creating competitive events for protocol optimization and “speedrunning challenges,” we’d target “hackers” of all experience levels.

article thumbnail

Targeting HER3 – a little wave of drug development that’s about to get a lot bigger

SugarCone Biotech

Once bound to HER3-expressing tumor cells, the ADC is designed to be internalized and the cytotoxic payload released to induce DNA damage and cell death. Drug development has also been hampered by serious adverse events, including Grade 3 or higher levels of neutropenia and interstitial lung disease. regulatory application in NSCLC.

article thumbnail

Rare Disease Day 2025: Rally for Rare Event Recap

Conversations in Drug Development Trends

The day inspires multiple events, such as fundraisers and scientific symposia, to bring together all the critical stakeholders who tirelessly work to make life better for those affected by rare diseases. In an incredible feat of collaboration, they were able to rapidly put together a new event called Rally for Rare.

article thumbnail

Breaking Barriers in Solid Tumor Research: Precision Medicine & Strategic Operations

Conversations in Drug Development Trends

This approach improves treatment outcomes over traditional broad-spectrum therapies, which are prone to more side effects and adverse events. Carefully crafted enrichment strategies optimize recruitment and enrollment, ensuring that the included participants will likely respond to the therapy.